Pancreatic Cancer Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (07/11/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage III Pancreatic Cancer Treatment

Added text to state that the international, randomized phase III LAP07 study provided prospective statistical data to indicate the role of chemoradiation therapy in the setting of gemcitabine-based induction chemotherapy, which showed no overall survival benefit. Of importance also is that the role of chemoradiation therapy in the setting of more active chemotherapy regimens including gemcitabine/paclitaxel and FOLFIRINOX has yet to be evaluated (cited Hammel et al. as reference 9 and level of evidence 1iiA).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Recurrent Pancreatic Cancer Treatment

Next section >
About This PDQ Summary